{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-003055","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.488305+00:00","generated_at":"2026-06-24T00:53:32.177641+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entera Bio reports Q2 results: submits EB613 protocol to FDA, net loss $7.0M, cash $17.3M","bullets":["Submitted proposed registrational protocol for EB613 (oral PTH) to FDA; expects Type C meeting in H2 2022.","Finalizing optimized formulation for EB612 (hypoparathyroidism); first-in-human PK study planned H1 2023.","Net loss $7.0M ($0.24 per share) for six months ended June 30, 2022, vs $4.9M ($0.21) in prior year period.","Revenue $112k, down from $226k; operating expenses $7.1M, up from $5.0M.","Cash $17.3M as of June 30, 2022, expected to fund operations through Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-003055","json":"https://secwatch.observer/filing/0001178913-22-003055.json","markdown":"https://secwatch.observer/filing/0001178913-22-003055.md","text":"https://secwatch.observer/filing/0001178913-22-003055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322003055/0001178913-22-003055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322003055/zk2228294.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:53:32.177641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}